Remission with Adalimumab after Interruption of Tr eatment : An Alternative Appr oach in Crohn ́ s Disease Management

Intr oduction: Adalimumab (ADA) is a fully-human anti-TNF-alpha antibody approved for the management of Crohn ́s disease (CD). In situations in which interruption of the tr eatment is mandatory, rescue therapy is contr oversial. Reinduction of remission with full dose may be an alternative in severe CD cases. There are no descriptions of this alternative in the literature. The aim of this study was to describe the experience with two patients treated with reinduction of remission with ADA, after interruption of tr eatment. Method: retrospective analysis of two patients in a cohor t of 24 CD patients treated with ADA, with case reports. Results: description of two young patients with fistulizing CD, with the need of interruption of ADA therapy due to different reasons (perianal abscess and difficulties in receiving the medication). Both were treated with reinduction of remission with full dose ADA regimen (160/80 mg), with good r esults and no adverse events. Conclusions: ther e are no studies in the literature comparing reinduction of remission with other possibilities of rescue therapy after interruption of treatment with any anti-TNF agent. Small case series like this, show good results with this alternative in selected and severe cases of CD.

[1]  F. Cornillie.  Ten years of infliximab (remicade) in clinical practice: the story from bench to bedside. , 2009, European journal of pharmacology.

[2]  P. G. Kotze,et al.  Análise de custo-minimização entre o Infliximabe (IFX) e o Adalimumabe (ADA) no tratamento da doença de Crohn (DC) , 2009 .

[3]  R. Nussenblatt,et al.  Infliximab for the treatment of active scleritis. , 2009, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[4]  M. Picco.  Adalimumab for the treatment of fistulas in patients with Crohn's disease , 2009 .

[5]  J. Colombel.  Efficacy and safety of adalimumab for the treatment of Crohn’s disease in adults , 2008, Expert review of gastroenterology & hepatology.

[6]  M. Regueiro,et al.  Infliximab dose intensification in Crohn's disease , 2007, Inflammatory bowel diseases.

[7]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[8]  P. Rutgeerts,et al.  Review article: infliximab therapy for inflammatory bowel disease – seven years on , 2006, Alimentary pharmacology & therapeutics.

[9]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[10]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[11]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .